You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 6,998,423


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 6,998,423
Title:Prevention of loss and restoration of bone mass by certain prostaglandin agonists
Abstract: Prostaglandin agonists, methods of using such prostaglandin agonists, pharmaceutical compositions containing such prostaglandin agonists and kits containing such prostaglandin agonists. The prostaglandin agonists are useful for the treatment of bone disorders including osteoporosis.
Inventor(s): Cameron; Kimberly O. (East Lyme, CT), Ke; Hua Z. (Ledyard, CT), Lefker; Bruce A. (Gales Ferry, CT), Rosati; Robert L. (Mystic, CT), Thompson; David D. (Gales Ferry, CT)
Assignee: Pfizer Inc. (New York, NY)
Application Number:10/652,188
Patent Claims:1. A compound having the Formula I ##STR00029## or a pharmaceutically acceptable salt or prodrug thereof pwherein either (i): B is N; A is (C.sub.1 C.sub.6)alkylsulfonyl, (C.sub.3 C.sub.7)cycloalkylsulfonyl, (C.sub.3 C.sub.7)cycloalkyl(C.sub.1 C.sub.6)alkylsulfonyl, said A moieties optionally mono-, di- or tri-substituted on carbon independently with hydroxy, (C.sub.1 C.sub.4)alkyl or halo; Q is --(C.sub.2 C.sub.6)alkylene-W--(C.sub.1 C.sub.3)alkylene-, --(C.sub.3 C.sub.8)alkylene-, said --(C.sub.3 C.sub.8)alkylene- optionally substituted with up to four substituents independently selected from fluoro or (C.sub.1 C.sub.4)alkyl, --X--(C.sub.1 C.sub.5)alkylene-, --(C.sub.1 C.sub.5)alkylene-X--, --(C.sub.1 C.sub.3)alkylene-X--(C.sub.1 C.sub.3)alkylene-, --(C.sub.2 C.sub.4)alkylene-W--X--(C.sub.0 C.sub.3)alkylene-, --(C.sub.0 C.sub.4)alkylene-X--W--(C.sub.1 C.sub.3)alkylene-, --(C.sub.2 C.sub.5)alkylene-W--X--W--(C.sub.1 C.sub.3)alkylene-, wherein the two occurrences of W are independent of each other, --(C.sub.1 C.sub.4)alkylene-ethenylene-(C.sub.1 C.sub.4)alkylene-, --(C.sub.1 C.sub.4)alkylene-ethenylene-(C.sub.0 C.sub.2)alkylene-X--(C.sub.0 C.sub.5)alkylene-, --(C.sub.1 C.sub.4)alkylene-ethenylene-(C.sub.0 C.sub.2)alkylene-X--W--(C.sub.1 C.sub.3)alkylene-, --(C.sub.1 C.sub.4)alkylene-ethynylene-(C.sub.1 C.sub.4)alkylene-, or --(C.sub.1 C.sub.4)alkylene-ethynylene-X--(C.sub.0 C.sub.3)alkylene-; W is oxy, thio, sulfino, sulfonyl, aminosulfonyl-, -mono-N--(C.sub.1 C.sub.4)alkyleneaminosulfonyl-, sulfonylamino, N--(C.sub.1 C.sub.4)alkylenesulfonylamino, carboxamido, N--(C.sub.1 C.sub.4)alkylenecarboxamido, carboxamidooxy, N--(C.sub.1 C.sub.4)alkylenecarboxamidooxy, carbamoyl, -mono-N--(C.sub.1 C.sub.4)alkylenecarbamoyl, carbamoyloxy, or -mono-N--(C.sub.1 C.sub.4)alkylenecarbamoyloxy, wherein said W alkyl groups are optionally substituted on carbon with one to three fluorines; X is a five or six membered aromatic ring optionally having one or two heteroatoms selected independently from oxygen, nitrogen, and sulfur; said ring optionally mono-, or di-substituted independently with halo, (C.sub.1 C.sub.3)alkyl, trifluoromethyl, trifluoromethyloxy, difluoromethyloxy, hydroxyl, (C.sub.1 C.sub.4)alkoxy, or carbamoyl; Z is carboxyl, (C.sub.1 C.sub.6)alkoxycarbonyl, tetrazolyl, 1,2,4-oxadiazolyl, 5-oxo-1,2,4-oxadiazolyl, (C.sub.1 C.sub.4)alkylsulfonylcarbamoyl or phenylsulfonylcarbamoyl; K is a bond, (C.sub.1 C.sub.8)alkylene, thio(C.sub.1 C.sub.4)alkylene or oxy(C.sub.1 C.sub.4)alkylene, said (C.sub.1 C.sub.8)alkylene optionally mono-unsaturated and wherein K is optionally mono-, di- or tri-substituted independently with fluoro, methyl or chloro; M is --Ar, --Ar.sup.1--V--Ar.sup.2, --Ar.sup.1--S--Ar.sup.2 or --Ar.sup.1--O--Ar.sup.2 wherein Ar, Ar.sup.1 and Ar.sup.2 are each independently a partially saturated, fully saturated or fully unsaturated five to eight membered ring optionally having one to four heteroatoms selected independently from oxygen, sulfur and nitrogen, or, a bicyclic ring consisting of two fused partially saturated, fully saturated or fully unsaturated five or six membered rings, taken independently, optionally having one to four heteroatoms selected independently from nitrogen, sulfur and oxygen; said Ar, Ar.sup.1 and Ar.sup.2 moieties optionally substituted, on one ring if the moiety is monocyclic, or one or both rings if the moiety is bicyclic, on carbon with up to three substituents independently selected from R.sup.1, R.sup.2 and R.sup.3 wherein R.sup.1, R.sup.2 and R.sup.3 are hydroxy, nitro, halo, (C.sub.1 C.sub.6)alkoxy, (C.sub.1 C.sub.4)alkoxy(C.sub.1 C.sub.4)alkyl, (C.sub.1 C.sub.4)alkoxycarbonyl, (C.sub.1 C.sub.7)alkyl, (C.sub.3 C.sub.7)cycloalkyl, (C.sub.3 C.sub.7)cycloalkyl(C.sub.1 C.sub.4)alkyl, (C.sub.3 C.sub.7)cycloalkyl(C.sub.1 C.sub.4)alkanoyl, formyl, (C.sub.1 C.sub.8)alkanoyl, (C.sub.1 C.sub.6)alkanoyl(C.sub.1 C.sub.6)alkyl, (C.sub.1 C.sub.4)alkanoylamino, (C.sub.1 C.sub.4)alkoxycarbonylamino, sulfonamido, (C.sub.1 C.sub.4)alkylsulfonamido, amino, mono-N-- or di-N,N--(C.sub.1 C.sub.4)alkylamino, carbamoyl, mono-N-- or di-N,N--(C.sub.1 C.sub.4)alkylcarbamoyl, cyano, thiol, (C.sub.1 C.sub.6)alkylthio, (C.sub.1 C.sub.6)alkylsulfinyl, (C.sub.1 C.sub.4)alkylsulfonyl or mono-N-- or di-N,N--(C.sub.1 C.sub.4)alkylaminosulfinyl; R.sup.1, R.sup.2 and R.sup.3 are optionally mono-, di- or tri-substituted on carbon independently with halo or hydroxy; and V is a bond or (C.sub.1 C.sub.3)alkylene optionally mono- or di-substituted independently with hydroxy or fluoro with the proviso that when K is (C.sub.2 C.sub.4)alkylene and M is Ar and Ar is cyclopent-1-yl, cyclohex-1-yl, cyclohept-1-yl or cyclooct-1-yl then said (C.sub.5 C.sub.8)cycloalkyl substituents are not substituted at the one position with hydroxy; or (ii): B is N; A is (C.sub.1 C.sub.6)alkanoyl, or (C.sub.3 C.sub.7)cycloalkyl(C.sub.1 C.sub.6)alkanoyl, said A moieties optionally mono-, di- or tri-substituted independently on carbon with hydroxy or halo; Q is --(C.sub.2 C.sub.6)alkylene-W--(C.sub.1 C.sub.3)alkylene-, --(C.sub.4 C.sub.8)alkylene-, said --(C.sub.4 C.sub.8)alkylene- optionally substituted with up to four substituents independently selected from fluoro or (C.sub.1 C.sub.4)alkyl, --X--(C.sub.2 C.sub.5)alkylene-, --(C.sub.1 C.sub.5)alkylene-X--, --(C.sub.1 C.sub.3)alkylene-X--(C.sub.1 C.sub.3)alkylene-, --(C.sub.2 C.sub.4)alkylene-W--X--(C.sub.0 C.sub.3)alkylene-, --(C.sub.0 C.sub.4)alkylene-X--W--(C.sub.1 C.sub.3)alkylene-, --(C.sub.2 C.sub.5)alkylene-W--X--W--(C.sub.1 C.sub.3)alkylene-, wherein the two occurrences of W are independent of each other, --(C.sub.1 C.sub.4)alkylene-ethenylene-(C.sub.1 C.sub.4)alkylene-, --(C.sub.1 C.sub.4)alkylene-ethenylene-(C.sub.0 C.sub.2)alkylene-X--(C.sub.0 C.sub.5)alkylene-, --(C.sub.1 C.sub.4)alkylene-ethenylene-(C.sub.0 C.sub.2)alkylene-X--W--(C.sub.1 C.sub.3)alkylene-, --(C.sub.1 C.sub.4)alkylene-ethynylene-(C.sub.1 C.sub.4)alkylene-, or --(C.sub.1 C.sub.4)alkylene-ethynylene-X--(C.sub.0 C.sub.3)alkylene-; W is oxy, thio, sulfino, sulfonyl, aminosulfonyl-, -mono-N--(C.sub.1 C.sub.4)alkyleneaminosulfonyl-, sulfonylamino, N--(C.sub.1 C.sub.4)alkylenesulfonylamino, carboxamido, N--(C.sub.1 C.sub.4)alkylenecarboxamido, carboxamidooxy, N--(C.sub.1 C.sub.4)alkylenecarboxamidooxy, carbamoyl, -mono-N--(C.sub.1 C.sub.4)alkylenecarbamoyl, carbamoyloxy, or -mono-N--(C.sub.1 C.sub.4)alkylenecarbamoyloxy, wherein said W alkyl groups are optionally substituted on carbon with one to three fluorines; X is a five or six membered aromatic ring optionally having one or two heteroatoms selected independently from oxygen, nitrogen, and sulfur; said ring optionally mono-, or di-substituted independently with halo, (C.sub.1 C.sub.3)alkyl, trifluoromethyl, trifluoromethyloxy, difluoromethyloxy, hydroxyl, (C.sub.1 C.sub.4)alkoxy, or carbamoyl; Z is carboxyl, (C.sub.1 C.sub.6)alkoxycarbonyl, tetrazolyl, 1,2,4-oxadiazolyl, 5-oxo-1,2,4-oxadiazolyl, (C.sub.1 C.sub.4)alkylsulfonylcarbamoyl or phenylsulfonylcarbamoyl; K is (C.sub.1 C.sub.8)alkylene, thio(C.sub.1 C.sub.4)alkylene or oxy(C.sub.1 C.sub.4)alkylene, said (C.sub.1 C.sub.8)alkylene optionally mono-unsaturated and wherein K is optionally mono-, di- or tri-substituted independently with fluoro, methyl or chloro; M is --Ar, --Ar.sup.1--V--Ar.sup.2, --Ar.sup.1--S--Ar.sup.2 or --Ar.sup.1--O--Ar.sup.2 wherein Ar, Ar.sup.1 and Ar.sup.2 are each independently a partially saturated, fully saturated or fully unsaturated five to eight membered ring optionally having one to four heteroatoms selected independently from oxygen, sulfur and nitrogen, or, a bicyclic ring consisting of two fused partially saturated, fully saturated or fully unsaturated five or six membered rings, taken independently, optionally having one to four heteroatoms selected independently from nitrogen, sulfur and oxygen; said Ar, Ar.sup.1 and Ar.sup.2 moieties optionally substituted, on one ring if the moiety is monocyclic, or one or both rings if the moiety is bicyclic, on carbon with up to three substituents independently selected from R.sup.1, R.sup.2 and R.sup.3 wherein R.sup.1, R.sup.2 and R.sup.3 are H, hydroxy, nitro, halo, (C.sub.1 C.sub.6)alkoxy, (C.sub.1 C.sub.4)alkoxy(C.sub.1 C.sub.4)alkyl, (C.sub.1 C.sub.4)alkoxycarbonyl, (C.sub.1 C.sub.7)alkyl, (C.sub.3 C.sub.7)cycloalkyl, (C.sub.3 C.sub.7)cycloalkyl(C.sub.1 C.sub.4)alkyl, (C.sub.3 C.sub.7)cycloalkyl(C.sub.1 C.sub.4)alkanoyl, formyl, (C.sub.1 C.sub.8)alkanoyl, (C.sub.1 C.sub.6)alkanoyl(C.sub.1 C.sub.6)alkyl, (C.sub.1 C.sub.4)alkanoylamino, (C.sub.1 C.sub.4)alkoxycarbonylamino, sulfonamido, (C.sub.1 C.sub.4)alkylsulfonamido, amino, mono-N-- or di-N,N--(C.sub.1 C.sub.4)alkylamino, carbamoyl, mono-N-- or di-N,N--(C.sub.1 C.sub.4)alkylcarbamoyl, cyano, thiol, (C.sub.1 C.sub.6)alkylthio, (C.sub.1 C.sub.6)alkylsulfinyl, (C.sub.1 C.sub.4)alkylsulfonyl or mono-N-- or di-N,N--(C.sub.1 C.sub.4)alkylaminosulfinyl; R.sup.1, R.sup.2 and R.sup.3 are optionally mono-, di- or tri-substituted independently on carbon with halo or hydroxy; and V is a bond or (C.sub.1 C.sub.3)alkylene optionally mono- or di-substituted independently with hydroxy or fluoro with the proviso that when K is (C.sub.2 C.sub.4)alkylene and M is Ar and Ar is cyclopent-1-yl, cyclohex-1-yl, cyclohept-1-yl or cycloct-1-yl then said (C.sub.5 C.sub.8)cycloalkyl substituents are not substituted at the one position with hydroxy and with the proviso that 6-[(3-phenyl-propyl)-(2-propyl-pentanoyl)-amino]-hexanoic acid and its ethyl ester are not included or (iii): B is C(H); A is (C.sub.1 C.sub.6)alkanoyl, or (C.sub.3 C.sub.7)cycloalkyl(C.sub.1 C.sub.6)alkanoyl, said A moieties optionally mono-, di- or tri-substituted on carbon independently with hydroxy or halo; Q is --(C.sub.2 C.sub.6)alkylene-W--(C.sub.1 C.sub.3)alkylene-, --(C.sub.4 C.sub.8)alkylene-, said --(C.sub.4 C.sub.8)alkylene- optionally substituted with up to four substituents independently selected from fluoro or (C.sub.1 C.sub.4)alkyl, --X--(C.sub.1 C.sub.5)alkylene-, --(C.sub.1 C.sub.5)alkylene-X--, --(C.sub.1 C.sub.3)alkylene-X--(C.sub.1 C.sub.3)alkylene-, --(C.sub.2 C.sub.4)alkylene-W--X--(C.sub.0 C.sub.3)alkylene-, --(C.sub.0 C.sub.4)alkylene-X--W--(C.sub.1 C.sub.3)alkylene-, --(C.sub.2 C.sub.5)alkylene-W--X--W--(C.sub.1 C.sub.3)alkylene-, wherein the two occurrences of W are independent of each other, --(C.sub.1 C.sub.4)alkylene-ethenylene-(C.sub.1 C.sub.4)alkylene-, --(C.sub.1 C.sub.4)alkylene-ethenylene-(C.sub.0 C.sub.2)alkylene-X--(C.sub.0 C.sub.5)alkylene-, --(C.sub.1 C.sub.4)alkylene-ethenylene-(C.sub.0 C.sub.2)alkylene-X--W--(C.sub.1 C.sub.3)alkylene-, --(C.sub.1 C.sub.4)alkylene-ethynylene-(C.sub.1 C.sub.4)alkylene-, or --(C.sub.1 C.sub.4)alkylene-ethynylene-X--(C.sub.0 C.sub.3)alkylene-; W is oxy, thio, sulfino, sulfonyl, aminosulfonyl-, -mono-N--(C.sub.1 C.sub.4)alkyleneaminosulfonyl-, sulfonylamino, N--(C.sub.1 C.sub.4)alkylenesulfonylamino, carboxamido, N--(C.sub.1 C.sub.4)alkylenecarboxamido, carboxamidooxy, N--(C.sub.1 C.sub.4)alkylenecarboxamidooxy, carbamoyl, -mono-N--(C.sub.1 C.sub.4)alkylenecarbamoyl, carbamoyloxy, or -mono-N--(C.sub.1 C.sub.4)alkylenecarbamoyloxy, wherein said W alkyl groups are optionally substituted on carbon with one to three fluorines; X is a five or six membered aromatic ring optionally having one or two heteroatoms selected independently from oxygen, nitrogen and sulfur; said ring optionally mono-, or di-substituted independently with halo, (C.sub.1 C.sub.3)alkyl, trifluoromethyl, trifluoromethyloxy, difluoromethyloxy, hydroxyl, (C.sub.1 C.sub.4)alkoxy, or carbamoyl; Z is carboxyl, (C.sub.1 C.sub.6)alkoxycarbonyl, tetrazolyl, 1,2,4-oxadiazolyl, 5-oxo-1,2,4-oxadiazolyl, (C.sub.1 C.sub.4)alkylsulfonylcarbamoyl or phenylsulfonylcarbamoyl; K is a bond, (C.sub.1 C.sub.8)alkylene, thio(C.sub.1 C.sub.4)alkylene, (C.sub.4 C.sub.7)cycloalkyl(C.sub.1 C.sub.6)alkylene or oxy(C.sub.1 C.sub.4)alkylene, said (C.sub.1 C.sub.8)alkylene optionally mono-unsaturated and wherein K is optionally mono-, di- or tri-substituted independently with fluoro, methyl or chloro; M is --Ar, --Ar.sup.1--V--Ar.sup.2, --Ar.sup.1--S--Ar.sup.2 or --Ar.sup.1--O--Ar.sup.2 wherein Ar, Ar.sup.1 and Ar.sup.2 are each independently a partially saturated, fully saturated or fully unsaturated five to eight membered ring optionally having one to four heteroatoms selected independently from oxygen, sulfur and nitrogen, or, a bicyclic ring consisting of two fused partially saturated, fully saturated or fully unsaturated five or six membered rings, taken independently, optionally having one to four heteroatoms selected independently from nitrogen, sulfur and oxygen; said Ar, Ar.sup.1 and Ar.sup.2 moieties optionally substituted, on one ring if the moiety is monocyclic, or one or both rings if the moiety is bicyclic, on carbon with up to three substituents independently selected from R.sup.1, R.sup.2 and R.sup.3 wherein R.sup.1, R.sup.2 and R.sup.3 are H, hydroxy, nitro, halo, (C.sub.1 C.sub.6)alkoxy, (C.sub.1 C.sub.4)alkoxy(C.sub.1 C.sub.4)alkyl, (C.sub.1 C.sub.4)alkoxycarbonyl, (C.sub.1 C.sub.7)alkyl, (C.sub.3 C.sub.7)cycloalkyl, (C.sub.3 C.sub.7)cycloalkyl(C.sub.1 C.sub.4)alkyl, (C.sub.3 C.sub.7)cycloalkyl(C.sub.1 C.sub.4)alkanoyl, formyl, (C.sub.1 C.sub.8)alkanoyl, (C.sub.1 C.sub.6)alkanoyl(C.sub.1 C.sub.6)alkyl, (C.sub.1 C.sub.4)alkanoylamino, (C.sub.1 C.sub.4)alkoxycarbonylamino, sulfonamido, (C.sub.1 C.sub.4)alkylsulfonamido, amino, mono-N-- or di-N,N--(C.sub.1 C.sub.4)alkylamino, carbamoyl, mono-N-- or di-N,N--(C.sub.1 C.sub.4)alkylcarbamoyl, cyano, thiol, (C.sub.1 C.sub.6)alkylthio, (C.sub.1 C.sub.6)alkylsulfinyl, (C.sub.1 C.sub.4)alkylsulfonyl or mono-N-- or di-N,N--(C.sub.1 C.sub.4)alkylaminosulfinyl; R.sup.1, R.sup.2 and R.sup.3 are optionally mono-, di- or tri-substituted on carbon independently with halo or hydroxy; and V is a bond or (C.sub.1 C.sub.3)alkylene optionally mono- or di-substituted independently with hydroxy or fluoro with the proviso that when K is (C.sub.2 C.sub.4)alkylene and M is Ar and Ar is cyclopent-1-yl, cyclohex-1-yl, cyclohept-1-yl or cyclooct-1-yl then said (C.sub.5 C.sub.8)cycloalkyl substituents are not substituted at the one position with hydroxy.

2. A compound selected from the group consisting of: 7-[(4-Butyl-benzyl)-methanesulfonyl-amino]-heptanoic acid; (3-{[(4-Butyl-benzyl)-methanesulfonyl-amino]-methyl}-phenyl)-acetic acid; 7-{[2-(3,5-Dichloro-phenoxy)-ethyl]-methanesulfonyl-amino}-heptanoic acid; 4-(2-([3-(3,5-Dichloro-phenyl)-allyl]-methanesulfonyl-amino}-ethyl)- -benzoic acid; 7-[Methanesulfonyl-(4-trifluoromethyl-benzyl)-amino]-heptanoic acid; Trans-7-[Methanesulfonyl-(3-phenyl-allyl)-amino]-heptanoic acid; Trans-(4-{(3-(3,5-Dichloro-phenyl)-allyl]-methanesulfonyl-amino}-butoxy)-- acetic acid; 7-{[4-(1-Hydroxy-hexyl)-benzyl]-methanesulfonyl-amino]-heptanoic acid; 7-[Methanesulfonyl-(2'-trifluoromethyl-biphenyl-4-ylmethyl)-amino]-heptan- oic acid; 7-[(2',6'-Dichloro-biphenyl-4-ylmethyl)-methanesulfonyl-amino]-h- eptanoic acid; 7-[Methanesulfonyl-(2-phenoxy-ethyl)-amino]-heptanoic acid; 7-[(Methylsulfonyl)[[4-(2-pyridinyl)phenyl]methyl]amino]-heptanoic acid; 7-[Methanesulfonyl-(5-phenyl-pentyl)-amino]-heptanoic acid; 7-{[2-(2,4-Dichloro-phenoxy)-ethyl]-methanesulfonyl-amino}-heptanoic acid; Trans-[3-({[3-(3,5-Dichloro-phenyl)-allyl]-methanesulfonyl-amino}-m- ethyl)-phenyl]-acetic acid; 7-{[3-(3,5-Dichloro-phenyl)-propyl]-methanesulfonyl-amino}-heptanoic acid; [3-({[3-(3-Chloro-phenyl)-propyl]-methanesulfonyl-amino}-methyl)-ph- enyl]-acetic acid; 7-[(2-Indan-2-yl-ethyl)-methanesulfonyl-amino]-heptanoic acid; 7-[Methanesulfonyl-(4-phenyl-butyl)-amino]-heptanoic acid; [3-({[2-(3,5-Dichloro-phenoxy)-ethyl]-methanesulfonyl-amino}-methyl)-phen- yl]-acetic acid; 4-(4-{[3-(3-Chloro-phenyl)-propyl]-methanesulfonyl-amino}-phenyl)-butyric acid; [2-(2-{[3-(3-Chloro-phenyl)-propyl]-methanesulfonyl-amino}-ethyl)-p- henoxy]-acetic acid; [3-({Methanesulfonyl-[3-(3-trifluoromethyl-phenyl)-propyl]-amino}-methyl)- -phenyl]-acetic acid; {4-[(4-Butyl-benzyl)-methanesulfonyl-amino]-butoxy}-acetic acid; 5-(3-{[3-(3-Chloro-phenyl)-propyl]-methanesulfonyl-amino}-propyl)-thiophe- ne-2-carboxylic acid; 7-{[5-(1-Hydroxy-hexyl)-thiophen-2-ylmethyl]-methanesulfonyl-amino}-hepta- noic acid; 5-{3-[(4-Butyl-benzyl)-methanosulfonyl-amino]-propyl}-thiophene- -2-carboxylic acid; Trans-7-{[3-(3,5-Difluoro-phenyl)-allyl]-methanesulfonyl-amino}-heptanoic acid; 7-{[3-(3-Chloro-phenyl)-propyl]-methanesulfonyl-amino}-heptanoic acid; Trans-5-(3-{[3-(3,5-Dichloro-phenyl-allyl]-methanesulfonyl-amino}-p- ropyl)-thiophene-2-carboxylic acid; 7-[(4-Isobutyl-benzyl)-methanesulfonyl-amino]-heptanoic acid; 7-{[3-(2-Chloro-phenyl)-propyl]-methanesulfonyl-amino}-heptanoic acid; 7-[(2'-Chloro-biphenyl-4-ylmethyl)-methanesulfonyl-amino]-heptanoic acid; 7-[(4-Benzyl-benzyl)-methanesulfonyl-amino]-heptanoic acid; Trans-[3-({[3,5-Dichloro-phenyl)-allyl]-methanesulfonyl-amino}-methyl)-ph- enoxy]-acetic acid; (4-{[(4-Butyl-benzyl)-methanesulfonyl-amino]-methyl}-phenoxy)-acetic acid; 3-(2-{[2-(3,5-Dichloro-phenoxy)-ethyl]-methanesulfonyl-amino}-ethox- y)-benzoic acid; 7-{[2-(3-chloro-phenoxy)-ethyl]-methanesulfonyl-amino}-heptanoic acid; 7-[(2'-Cyano-biphenyl-4-ylmethyl)-methanesulfonyl-amino]-heptanoic acid; 5-(3-{[2-(3,5-Dimethyl-phenoxy)-ethyl]-methanesulfonyl-amino}-propyl)-thi- ophene-2-carboxylic acid; 5-(3-{[2-(3,5-Dimethoxy-phenoxy)-ethyl]-methanesulfonyl-amino}-propyl)-th- iophene-2-carboxylic acid; 5-(3-{[2-(3,5-Dichloro-phenoxy)-ethyl]-methanesulfonyl-amino}-propyl)-thi- ophene-2-carboxylic acid; [3-({[3-Chloro-phenyl)-propyl]methanesulfonyl-amino}-methyl)-phenoxy]-ace- tic acid; [3-({[2-(3,5-Dichloro-phenoxy)-ethyl]-methanesulfonyl-amino}-met- hyl)-phenoxy]-acetic acid; Trans-7-{[3-(3-Hydroxy-phenyl-allyl]-methanesulfonyl-amino}-heptanoic acid; Trans-7-{[3-(2-Hydroxy-phenyl)-allyl]-methanesulfonyl-amino}-heptan- oic acid; Trans-7-{[(3-(3-Hydroxymethyl-phenyl)-allyl]-methanesulfonyl-ami- no}-heptanoic acid; Trans-7-{[3-(3,5-Dichloro-phenyl)-allyl]-methanesulfonyl-amino}-heptanoic acid; Trans-7-{[3-(3,5-Bis-trifluoromethyl-phenyl)-allyl]-methanesulfonyl- -amino}-heptanoic acid; Trans-7-[Methanesulfonyl-(4-phenyl-but-3-enyl)-amino]-heptanoic acid; 7-{[3-(3,5-Bis-trifluoromethyl-phenyl)-propyl]methanesulfonyl-amino}-hept- anoic acid; 7-[Methanesulfonyl-(3-phenyl-propyl)-amino]-heptanoic acid; 7-[Methanesulfonyl-(3-m-tolyl-propyl)-amino]-heptanoic acid; 7-{[3-(3,5-Difluoro-phenyl)-propyl]-methanesulfonyl-amino}-heptanoic acid; 7-{[4-(1-Hydroxy-3-pheny-propyl)-benzyl]methanesulfonyl-amino}-hept- anoic acid; 7-{[4-(1-Hydroxy-pentyl)-benzyl]-methanesulfonyl-amino}-heptanoic acid; 7-{[4-(1-Hydroxy-2-phenyl-ethyl)-benzyl]-methanesulfonyl-amino}-heptanoic acid; 7-{[2'-(1-Hydroxy-hexyl)-biphenyl-4-ylmethyl]-methanesulfonyl-amino- }-heptanoic acid; Trans-N-[3-(3,5-Dichloro-phenyl)-allyl]-N-[6-(1H-tetrazol-5-yl)-hexyl]-me- thanesulfonamide; N-(4-Butyl-benzyl)-N-[6-(2H-tetrazol-5-yl)-hexyl]-methanesulfonamide; N-[2-(3,5-Dichloro-phenoxy)-ethyl]-N-[6-(1H-tetrazol-5-yl)-hexyl]-methane- sulfonamide; 7-[(2-Hydroxymethyl-biphenyl-4-ylmethyl)-methanesulfonyl-amino]-heptanoic acid; 7-(Biphenyl-4-ylmethyl-methanesulfonyl-amino)-heptanoic acid; 7-[(2'-Formyl-biphenyl-4-ylmethyl)-methanesulfonyl-amino]-heptanoic acid; 7-{[4-(3-Hydroxymethyl-thiophen-2-yl)-benzyl]-methanesulfonyl-amino}-hept- anoic acid; 7-[(4-Hexanoyl-benzyl)-methanesulfonyl-amino]-heptanoic acid; (4-{2-[(4-Butyl-benzyl)-methanesulfonyl-amino]-ethyl}-phenyl)-acetic acid; 7-[[4-(1-Hydroxy-hexyl)-benzyl]-(propane-1-sulfonyl)-amino]-heptano- ic acid; 7-[Methanesulfonyl-(4-phenyl-thiophen-2-ylmethyl)-amino]-heptanoi- c acid; 7-{[4-(1-Hydroxy-hexyl)-benzyl]-propionyl-amino}-heptanoic acid; 7-{Butyryl-[4-(1-hydroxy-hexyl)-benzyl]-amino}-heptanoic acid; 7-[(4-Butyl-benzyl)-propionyl-amino]-heptanoic acid; 7-[Methanesulfonyl-(4-phenethyl-benzyl)-amino]-heptanoic acid; Trans-4-{2-[Methanesulfonyl-(3-phenyl-allyl)-amino]-ethoxy}-benzoic acid; 5-{3-[(6-Chloro-quinolin-2-ylmethyl)-methanesulfonyl-amino]-propyl}-thiop- hene-2-carboxylic acid; 5-{3-[2-(3,5-Bis-trifluoromethyl-phenoxy)-ethyl]-methanesulfonyl-amino}-p- ropyl)-thiophene-2-carboxylic acid; 5-(3-[Methanesulfonyl-[2-(3-methoxy-phenoxy)-ethyl]-amino}-propyl)-thioph- ene-2-carboxylic acid; 7-{[3-(3-Chloro-5-methoxy-phenoxy)-propyl]methanesulfonyl-amino}-heptanoi- c acid; 5-(3-{[3-(3-Chloro-5-methoxy-phenoxy)-propyl]-methanesulfonyl-amin- o}-propyl)-thiophene-2-carboxylic acid; 5-(3-{[3-(3,5-Dichloro-phenoxy)-propyl]-methanesulfonyl-amino}-propyl)-th- iophene-2-carboxylic acid; 5-(3-{[2-(3-Ethyl-phenoxy)-ethyl]-methanesulfonyl-amino}-propyl)-thiophen- e-2-carboxylic acid; 5-(3-{[2-(3-Isopropyl-phenoxy)-ethyl]-methanesulfonyl-amino}-propyl)-thio- phene-2-carboxylic acid; 5-(3-{Methanesulfonyl-[2-(3-trifluoromethyl-phenoxy)-ethyl]-amino}-propyl- )-thiophene-2-carboxylic acid; 2-(3-{[2-(3,5-Dichloro-phenoxy)-ethyl]-methanesulfonyl-amino}-propyl)-thi- azole-4-carboxylic acid; 5-{3-[Methanesulfonyl-(3-phenyl-propyl)-amino]-propyl}-thiophene-2-carbox- ylic acid; 7-{[3-(3,5-Dichloro-phenoxy)-propyl]methanesulfonyl-amino}-hept- anoic acid; 5-(3-{Methanesulfonyl-[2-(3-fluoro-phenoxy)-ethyl]-amino}-propyl)-thiophe- ne-2-carboxylic acid; 5-(3-{Methanesulfonyl-[3-(3-methoxy-phenyl)-propyl]-amino}-propyl]-thioph- ene-2-carboxylic acid; 5-[3-(Benzofuran-2-ylmethyl-methanesulfonyl-amino)-propyl]-thiophene-2-ca- rboxylic acid; 5-(3-{[2-(3-Chloro-5-methoxy-phenoxy)-ethyl]-methanesulfonyl-amino}-propy- l)-thiophene-2-carboxylic acid; 5-(3-{[2-(3-Ethoxy-phenoxy)-ethyl]-methanesulfonyl-amino}-propyl)-thiophe- ne-2-carboxylic acid; (4-{[2-(3,5-Dichloro-phenoxy)-ethyl]-methanesulfonyl-amino}-butoxy)-aceti- c acid; (3-{[(4-Butoxy-benzyl)-methanesulfonyl-amino]-methyl}-phenyl)-acet- ic acid; 7-[(4-Butoxy-benzyl)-methanesulfonyl-amino]-heptanoic acid; 7-[(6-Chloro-quinolin-2-ylmethyl)-methanesulfonyl-amino]-heptanoic acid; {3-[(Benzofuran-2-ylmethyl-methanesulfonyl-amino)-methyl-phenyl}-acetic acid; (3-{[(4-Ethyl-benzyl)-methanesulfonyl-amino]-methyl}-phenyl)-acetic acid; (3-{[Methanesulfonyl-(4-propyl-benzyl)-amino]-methyl}-phenyl)-aceti- c acid; (3-{[(4-Benzyl-benzyl)-methanesulfonyl-amino]-methyl}-phenyl)-acet- ic acid; (3-{[(4-Butyl-benzyl)-(propane-1-sulfonyl)-amino]-methyl}-phenyl)- -acetic acid; 7-{Methanesulfonyl-[3-(5-methyl-thiophen-2-yl)-propyl]amino}-heptanoic acid; 5-{3-[(3-Furan-2-yl-propyl)-methanesulfonyl-amino]-propyl}-thiophen- e-2-carboxylic acid; 7-{Methanesulfonyl-[3-(3-methoxyphenyl)-propyl]-amino}-heptanoic acid; [3-({[4-(1-Hydroxy-hexyl)-benzyl]-methanesulfonyl-amino}-methyl)-phenyl]-- acetic acid; 5-(3-{[2-(3-Chloro-phenoxy)-ethyl]-methanesulfonyl-amino}-propyl)-thiophe- ne-2-carboxylic acid; 2-{3-[Methanesulfonyl-(3-phenyl-propyl)-amino]-propyl}-thiazole-4-carboxy- lic acid; 2-(3-{[3-(3-Chloro-phenyl)-propyl]-methanesulfonyl-amino}-propyl- )-thiazole-4-carboxylic acid; 2-{3-[(4-Butyl-benzyl-methanesulfonyl-amino]-propyl}-thiazole-4-carboxyli- c acid; (5-{[(4-Isobutyl-benzyl)-methanesulfonyl-amino]-methyl}-thiophen-2- -yl)-acetic acid; 2-{3-[(4-Butyl-benzyl)-methanesulfonyl-amino]-propyl}-thiazole-4-carboxyl- ic acid; 7-{[2-(3,5-Dichloro-phenoxy)-ethyl]-methanesulfonyl-amino}-heptan- oic acid; [5-({[3-(3-Chloro-phenyl)-propyl]-methanesulfonyl-amino}-methyl)- -thiophen-2-yl]-acetic acid; [5-({[2-(3,5-Dichloro-phenoxy)-ethyl]-methanesulfonyl-amino}-methyl)-thio- phen-2-yl]-acetic acid; (5-{[(4-Butyl-benzyl)-methanesulfonyl-amino]-methyl]-thiophen-2-yl)-aceti- c acid; 5-(3-{[2-(3-Dichloro-phenoxy)-ethyl]-methanesulfonyl-amino}-propyl- )-furan-2-carboxylic acid; Trans-5-(3-{[3-(3,5-Dichloro-phenyl)-allyl]-methanesulfonyl-amino}-propyl- )-furan-2-carboxylic acid; 3-(2-{[2-(3,5-Dichloro-phenoxy)-ethyl]-methanesulfonyl-amino}-ethyl)-benz- olic acid; [3-(3-{[3-(3-Chloro-phenyl)-propyl]-methanesulfonyl-amino}-prop- yl)-phenyl]-acetic acid; 5-{3-[(3-Benzo[1,3]dioxol-5-yl-propyl)-methanesulfonyl-amino]-propyl}-thi- ophene-2-carboxylic acid; (3-{[(4-Isobutyl-benzyl)-methanesulfonyl-amino]-methyl}-phenyl)-acetic acid; 7-[(4-Isopropyl-benzyl)-methanesulfonyl-amino]-heptanoic acid; 7-{[2-(3,5-Difluoro-phenoxy)-ethyl]-methanesulfonyl-amino}-heptanoic acid; 7-{[2-(3,5-Dimethyl-phenoxy)-ethyl]-methanesulfonyl-amino}-heptanoi- c acid; (2-{3-[(4-Butyl-benzyl)-methanesulfonyl-amino]-propyl}-phenyl)-ace- tic acid; 5-(3-{[2-(Benzo[1,3]dioxol-5-yloxy)-ethyl]-methanesulfonyl-amino- }-propyl)-thiophene-2-carboxylic acid; [3-({[2-(3-Chloro-phenoxy)-ethyl]-methanesulfonyl-amino}-methyl)-phenyl]-- acetic acid; [3-(2-{[3-(3-Chloro-phenyl)-propyl]-methanesulfonyl-amino}-ethyl)-phenyl]- -acetic acid; [3-(2-{[2-(3,5-Dichloro-phenoxy)-ethyl]-methanesulfonyl-amino}-ethyl)-phe- nyl]-acetic acid; 5-(3-{[3-(3-Chloro-phenyl)-propyl]-trifluoroacetyl-amino}-propyl)-thiophe- ne-2-carboxylic acid; (3-{[(2,3-Dihydro-benzo[1,4]dioxin-5-ylmethyl)-methanesulfonyl-amino]-met- hyl}-phenyl)-acetic acid; (3-{[(5-Ethyl-thiophen-2-ylmethyl)-methanesulfonyl-amino]-methyl}-phenyl)- -acetic acid; (3-{[Methanesulfonyl-(5-phenyl-furan-2-ylmethyl)-amino]-methyl}-phenyl)-a- cetic acid; (3-{[(3-Hydroxy-4-propoxy-benzyl)-methanesulfonyl-amino]-methyl}-phenyl)-- acetic acid; [3-({[2-(4-Chloro-phenylsulfanyl)-ethyl]-methanesulfonyl-amino}-methyl)-p- henyl]-acetic acid; (3-{[Methanesulfonyl-(4-phenethylsulfanyl-benzyl)-amino]-methyl}phenyl)-a- cetic acid; [3-({[3-(3,5-Dichloro-phenoxy)-benzyl]-methanesulfonyl-amino}-methyl)-phe- nyl]-acetic acid; (3-{[Methanesulfonyl-(4-pyrimidin-2-yl-benzyl)-amino]-methyl}-phenyl)-ace- tic acid; (3-{[Methanesulfonyl-(4-thiazol-2-yl-benzyl)-amino]-methyl}-phen- yl)-acetic acid; (3-{[(4-Benzyl-3-hydroxy-benzyl)-methanesulfonyl-amino]-methyl}-phenyl-ac- etic acid; (3-{[Methanesulfonyl-(4-pyrazin-2-yl-benzyl)-amino]-methyl}-phe- nyl)-acetic acid; (3-{[Methanesulfonyl-(4-phenoxy-benzyl)-amino]-methyl}-phenyl)-acetic acid; [3-({(Methanesulfonyl-[4-(4-methyl-[1,2,3]triazol-1-yl)-benzyl]-ami- no}-methyl)-phenyl]-acetic acid; [3-({Methanesulfonyl-[4-(2-oxo-pyrrolidin-1-yl)-benzyl]-amino}-methyl-phe- nyl]-acetic acid; 5-{3-[(2,3-Dihydro-benzo[1,4]dioxin-6-ylmethyl)-methanesulfonyl-amino]-pr- opyl}-thiophene-2-carboxylic acid; (3-{[(4-Ethoxy-benzyl)-methanesulfonyl-amino]-methyl}-phenyl)-acetic acid; (3-{[(4-Dimethylamino-benzyl)-methanesulfonyl-amino]-methyl}-phenyl- )-acetic acid; (3-{[(4-Cyclohexyl-benzyl)-methanesulfonyl-amino]-methyl}-phenyl)-acetic acid; 5-{3-[(4-Dimethylamino-benzyl)-methanesulfonyl-amino]-propyl}-thiop- hene-2-carboxylic acid; (3-{[Methanesulfonyl-(4-pentyl-benzyl)-amino]-methyl}-phenyl)-acetic acid; (3-{[(4-Isopropoxy-benzyl)-methanesulfonyl-amino]-methyl}-phenyl)-a- cetic acid; (3-{[Methanesulfonyl-(4-pyrimidin-5-yl-benzyl)-amino]-methyl}-phenyl)-ace- tic acid; (3-{[Methanesulfonyl-(4-methyl-benzyl)-amino]-methyl}-phenyl)-ac- etic acid; (3-{[(4-tert-Butyl-benzyl)-methanesulfonyl-amino]-methyl}-pheny- l)-acetic acid; (3-{[(4-tert-Butyl-benzyl)-methanesulfonyl-amino]-methyl}-phenoxy)-acetic acid; (3-{[Methanesulfonyl-(4-trifluoromethoxy-benzyl)-amino]-methyl}-phe- nyl)-acetic acid; [3-({[3-(4-Chloro-phenyl)-propyl]-methanesulfonyl-amino}-methyl)-phenyl]-- acetic acid; (3-([Methanesulfonyl-(3-trifluoromethoxy-benzyl)-amino]-methyl}-phenyl)-a- cetic acid; [3-({[2-(3-Chloro-phenylsulfanyl)-ethyl]-methanesulfonyl-amino}-methyl)-p- henyl]-acetic acid; [3-({[4-(2-Benzo[1,3]dioxol-5-yl-vinyl)-benzyl]-methanesulfonyl-amino}-me- thyl)-phenyl]-acetic acid; (3-{[Methanesulfonyl-(4-thiazol-2-yl-benzyl)-amino]-methyl}-phenoxy)-acet- ic acid; (3-{[Methanesulfonyl-(4-pyridin-2-yl-benzyl)-amino]-methyl}-pheno- xy)-acetic acid; 5-{3-[(2-Benzylsulfanyl-ethyl)-methanesulfonyl-amino]-propyl}-thiophene-2- -carboxylic acid; 5-(3-{[2-(Biphenyl-2-yloxy)-ethyl]-methanesulfonyl-amino}-propyl)-thiophe- ne-2-carboxylic acid; 5-(3-{[3-(1H-Indol-3-yl)-propyl]-methanesulfonyl-amino}-propyl)-thiophene- -2-carboxylic acid; 5-{3-[(4-tert-Butyl-benzyl)-methanesulfonyl-amino]-propyl}-thiophene-2-ca- rboxylic acid; 5-(3-{[2-(3-Chloro-phenylsulfanyl)-ethyl]-methanesulfonyl-amino}-propyl)-- thiophene-2-carboxylic acid; (3-{[Methanesulfonyl-(4-pyridin-3-yl-benzyl)-amino]-methyl}-phenoxy)-acet- ic acid; 5-(3-{[3-(3-Bromo-phenyl)-propyl]-methanesulfonyl-amino}-propyl)-- thiophene-2-carboxylic acid;

5-(3-{(Butane-1-sulfonyl)-[3-(3-chloro-phenyl)-propyl]-amino}-propyl)-thi- ophene-2-carboxylic acid; 5-{3-[Cyclopropanecarbonyl-(2,3-dihydro-benzo[1,4]dioxin-6-ylmethyl)-amin- o]-propyl}-thiophene-2-carboxylic acid; 5-[3-(Benzofuran-2-ylmethyl-cyclopropanecarbonyl-amino)-propyl]-thiophene- -2-carboxylic acid; 5-(3-{[3-(3-Chloro-phenyl)-propyl]-propionyl-amino}-propyl)-thiophene-2-c- arboxylic acid; 5-(3-{Acetyl-[3-(3-chloro-phenyl)-propyl]-amino}-propyl)-thiophene-2-carb- oxylic acid; 5-{3-[(4-Butyl-benzyl)-(propane-1-sulfonyl)-amino]-propyl}-thiophene-2-ca- rboxylic acid; (3-{[(Benzo[1,2,5]oxadiazole-4-sulfonyl)-(4-butyl-benzyl)-amino]-methyl}-- phenyl)-acetic acid; (3-{[(4-Butyl-benzyl)-(propane-1-sulfonyl)-amino]-methyl}-phenyl)-acetic acid; (3-{[(4-Butyl-benzyl)-(thiophene-2-sulfonyl)-amino]-methyl}-phenyl)- -acetic acid; 3-(3-{[3-(3-Chloro-phenyl)-propyl]-methanesulfonyl-amino}-propyl)-benzoic acid; 5-(3-{[3-(3-Chloro-phenyl)-propyl]-methanesulfonyl-amino}-propyl)-f- uran-2-carboxylic acid; 5-(3-{[3-(3-Chloro-phenyl)-propyl]-methanesulfonyl-amino}-propyl)-tetrahy- drofuran-2-carboxylic acid; 5-(3-{[3-(3-Chloro-phenyl)-propyl]-ethanesulfonyl-amino}-propyl)-furan-2-- carboxylic acid; 5-{3-[(4-Butyl-benzyl)-ethanesulfonyl-amino]-propyl}-thiophene-2-carboxyl- ic acid; 5-(3-{[3-(3-Chloro-phenyl)-propyl]-ethanesulfonyl-amino}-propyl)-- thiophene-2-carboxylic acid; 3-(3-{[3-(3-Chloro-phenyl)-propyl]-ethanesulfonyl-amino}-propyl)-benzoic acid; 5-{3-[[3-(3-Chloro-phenyl)-propyl]-(propane-1-sulfonyl)-amino]-prop- yl}-thiophene-2-carboxylic acid; 5-{3-[[3-(3-Chloro-phenyl)-propyl]-(3-chloro-propane-1-sulfonyl)-amino]-p- ropyl}-thiophene-2-carboxylic acid; 5-(3-{[3-(3-Chloro-phenyl)-propyl]-hydroxyacetyl-amino}-propyl)-thiophene- -2-carboxylic acid; 5-(3-{[3-(3-Chloro-phenyl)-propyl]-cyclopropanecarbonyl-amino}-propyl)-th- iophene-2-carboxylic acid; 5-(3-{[3-(3-Chloro-phenyl)-propyl]-cyclobutanecarbonyl-amino}-propyl)-thi- ophene-2-carboxylic acid; 5-(3-{[3-(3-Chloro-phenyl)-propyl]-methoxyacetyl-amino}-propyl)-thiophene- -2-carboxylic acid; 5-(3-{Butyryl-[3-(3-chloro-phenyl)-propyl]-amino}-propyl)-thiophene-2-car- boxylic acid; 5-(3-{[3-(3-Chloro-phenyl)-propyl]-propionyl-amino}-propyl)-furan-2-carbo- xylic acid; 5(3-{[3-(3-Chloro-phenyl)-propyl]-cyclopropanecarbonyl-amino}-propyl)-fur- an-2-carboxylic acid; 5-(3-{Acetyl-[3-(3-chloro-phenyl)-propyl]-amino}-propyl)-furan-2-carboxyl- ic acid; 5-(3-{[3-(3-Chloro-phenyl)-propyl]-methanesulfonyl-amino}-propyl)- -thiophene-2-carboxylic acid; (3-{[(4-Butyl-benzyl)-methanesulfonyl-amino]-methyl}-phenyl)-acetic acid; [3-({[3-(3,5-Dichloro-phenyl)-allyl]-methanesulfonyl-amino}-methyl-phenox- y]-acetic acid; [3-({[2-(3,5-Dichloro-phenoxy)-ethyl]-methanesulfonyl-amino}-methyl)-phen- oxy]-acetic acid; 2-(3-{[2-(3,5-Dichloro-phenoxy)-ethyl]-methanesulfonyl-amino}-propyl)-thi- azole-4-carboxylic acid; N-[2-(3,5-Dichloro-phenoxy)-ethyl]-N-[6-(1H-tetrazol-5-yl)-hexyl]-methane- sulfonamide; 7-{[2-(3,5-Dichloro-phenoxy)-ethyl]-methanesulfonyl-amino}-heptanoic acid; 7-[(4-Butyl-benzyl)-methanesulfonyl-amino]-heptanoic acid; (3-{[(4-Cyclohexyl-benzyl)-methanesulfonyl-amino]-methyl}-phenyl)-acetic acid; (3-{[(4-tert-Butyl-benzyl)-methanesulfonyl-amino]-methyl}-phenoxy)-- acetic acid; and 5-(3-{[2-(3,5-Dichloro-phenoxy)-ethyl]-methanesulfonyl-amino}-propyl)-thi- ophene-2-carboxylic acid, or a pharmaceutically acceptable salt thereof.

3. A compound as recited in claim 2 selected from the group consisting of: 7-[(4-Butyl-benzyl)-methanesulfonyl-amino]-heptanoic acid; 7-{[2-(3,5-Dichloro-phenoxy)-ethyl]-methanesulfonyl-amino}-heptanoic acid; 7-[Methanesulfonyl-(4-trifluoromethyl-benzyl)-amino]-heptanoic acid; Trans-7-[Methanesulfonyl-(3-phenyl-allyl)-amino]-heptanoic acid; 7-{[4-(1-Hydroxy-hexyl)-benzyl]-methanesulfonyl-amino]-heptanoic acid; 7-[Methanesulfonyl-(2'-trifluoromethyl-biphenyl-4-ylmethyl)-amino]-heptan- oic acid; 7-[(2',6'-Dichloro-biphenyl-4-ylmethyl)-methanesulfonyl-amino]-h- eptanoic acid; 7-[Methanesulfonyl-(2-phenoxy-ethyl)-amino]-heptanoic acid; 7-[(Methylsulfonyl)[[4-(2-pyridinyl)phenyl]methyl]amino]-heptanoic acid; 7-[Methanesulfonyl-(5-phenyl-pentyl)-amino]-heptanoic acid; 7-{[2-(2,4-Dichloro-phenoxy)-ethyl]-methanesulfonyl-amino}-heptanoic acid; 7-{[3-(3,5-Dichloro-phenyl)-propyl]-methanesulfonyl-amino}-heptanoi- c acid; 7-[(2-Indan-2-yl-ethyl)-methanesulfonyl-amino]-heptanoic acid; 7-[Methanesulfonyl-(4-phenyl-butyl)-amino]-heptanoic acid; 7-{[5-(1-Hydroxy-hexyl)-thiophen-2-ylmethyl]-methanesulfonyl-amino}-hepta- noic acid; Trans-7-{[3-(3,5-Difluoro-phenyl)-allyl]-methanesulfonyl-amino}- -heptanoic acid; 7-{[3-(3-Chloro-phenyl)-propyl]methanesulfonyl-amino}-heptanoic acid; 7-[(4-Isobutyl-benzyl)-methanesulfonyl-amino]-heptanoic acid; 7-{[3-(2-Chloro-phenyl)-propyl]-methanesulfonyl-amino}-heptanoic acid; 7-[(2'-Chloro-biphenyl-4-ylmethyl)-methanesulfonyl-amino]-heptanoic acid; 7-[(4-Benzyl-benzyl)-methanesulfonyl-amino]-heptanoic acid; 7-{[2-(3-Chloro-phenoxy)-ethyl]-methanesulfonyl-amino}-heptanoic acid; 7-[(2'-Cyano-biphenyl-4-ylmethyl)-methanesulfonyl-amino]-heptanoic acid; Trans-7-{[3-(3-Hydroxy-phenyl)-allyl]-methanesulfonyl-amino}-heptanoic acid; Trans-7-{[3-(2-Hydroxy-phenyl)-allyl]-methanesulfonyl-amino}-heptan- oic acid; Trans-7-{[3-(3-Hydroxymethyl-phenyl)-allyl]-methanesulfonyl-amin- o}heptanoic acid; Trans-7-{[3-(3,5-Dichloro-phenyl)-allyl]-methanesulfonyl-amino}-heptanoic acid; Trans-7-{[3-(3,5-Bis-trifluoromethyl-phenyl)-allyl]-methanesulfonyl- -amino}-heptanoic acid; Trans-7-[Methanesulfonyl-(4-phenyl-but-3-enyl)-amino]-heptanoic acid; 7-{[3-(3,5-Bis-trifluoromethyl-phenyl)-propyl]-methanesulfonyl-amino}-hep- tanoic acid; 7-[Methanesulfonyl-(3-phenyl-propyl)-amino]-heptanoic acid; 7-[Methanesulfonyl-(3-m-tolyl-propyl)-amino]-heptanoic acid; 7-{[3-(3,5-Difluoro-phenyl)-propyl]-methanesulfonyl-amino}-heptanoic acid; 7-{[4-(1-Hydroxy-3-phenyl-propyl)-benzyl]-methanesulfonyl-amino}-he- ptanoic acid; 7-{[4-(1-Hydroxy-pentyl)-benzyl]-methanesulfonyl-amino}-heptanoic acid; 7-{[4-(1-Hydroxy-2-phenyl-ethyl)-benzyl]-methanesulfonyl-amino}-heptanoic acid; 7-{[2'-(1-Hydroxy-hexyl)-biphenyl-4-ylmethyl]-methanesulfonyl-amino- }-heptanoic acid; 7-[(2'-Hydroxymethyl-biphenyl-4-ylmethyl)-methanesulfonyl-amino]-heptanoi- c acid; 7-(Biphenyl-4-ylmethyl-methanesulfonyl-amino)-heptanoic acid; 7-[(2'-Formyl-biphenyl-4-ylmethyl)-methanesulfonyl-amino]-heptanoic acid; 7-{[4-(3-Hydroxymethyl-thiophen-2-yl)-benzyl]-methanesulfonyl-amino}-hept- anoic acid; 7-[(4-Hexanoyl-benzyl)-methanesulfonyl-amino]-heptanoic acid; 7-[[4-(1-Hydroxy-hexyl)-benzyl]-(propane-1-sulfonyl)-amino]-heptanoic acid; 7-[Methanesulfonyl-(4-phenyl-thiophen-2-ylmethyl)-amino]-heptanoic acid; 7-{[4-(1-Hydroxy-hexyl)-benzyl]-propionyl-amino}-heptanoic acid; 7-{Butyryl-[4-(1-hydroxy-hexyl)-benzyl]-amino}-heptanoic acid; 7-[(4-Butyl-benzyl)-propionyl-amino]-heptanoic acid; 7-[Methanesulfonyl-(4-phenethyl-benzyl)-amino]-heptanoic acid; 7-{[3-(3-Chloro-5-methoxy-phenoxy)-propyl]-methanesulfonyl-amino}-heptano- ic acid; 7-{[3-(3,5-Dichloro-phenoxy)-propyl]-methanesulfonyl-amino}-hepta- noic acid; 7-[(4-Butoxy-benzyl)-methanesulfonyl-amino]-heptanoic acid; 7-[(6-Chloro-quinolin-2-ylmethyl)-methanesulfonyl-amino]-heptanoic acid; 7-{Methanesulfonyl-[3-(5-methyl-thiophen-2-yl)-propyl]-amino}-heptanoic acid; 7-{Methanesulfonyl-[3-(3-methoxyphenyl)-propyl]-amino}-heptanoic acid; 7-{[2-(3,5-Dichloro-phenoxy)-ethyl]-methanesulfonyl-amino}-heptanoi- c acid; 7-[(4-Isopropyl-benzyl)-methanesulfonyl-amino]-heptanoic acid; 7-{[2-(3,5-Difluoro-phenoxy)-ethyl]-methanesulfonyl-amino}-heptanoic acid; 7-{[2-(3,5-Dimethyl-phenoxy)-ethyl]-methanesulfonyl-amino}-heptanoi- c acid; 7-{[2-(3,5-Dichloro-phenoxy)-ethyl]-methanesulfonyl-amino}-heptano- ic acid; and 7-[(4-Butyl-benzyl)-methanesulfonyl-amino]-heptanoic acid, or a pharmaceutically acceptable salt thereof.

4. A compound as recited in claim 2 selected from the group consisting of: (3-{[(4-Butyl-benzyl)-methanesulfonyl-amino]-methyl}-phenyl)-acetic acid; Trans-(4-{[3-(3,5-Dichloro-phenyl)-allyl]-methanesulfonyl-amino}-bu- toxy)-acetic acid; Trans-[3-({[3-(3,5-Dichloro-phenyl)-allyl]-methanesulfonyl-amino}-methyl)- -phenyl]-acetic acid; [3-({[3-(3-Chloro-phenyl)-propyl]-methanesulfonyl-amino}-methyl)-phenyl]-- acetic acid; [3-({[2-(3,5-Dichloro-phenoxy)-ethyl]-methanesulfonyl-amino}-methyl)-phen- yl]-acetic acid; [2-(2-{[3-(3-Chloro-phenyl)-propyl]-methanesulfonyl-amino}-ethyl)-phenoxy- ]-acetic acid; [3-({Methanesulfonyl-[3-(3-trifluoromethyl-phenyl)-propyl]-amino}-methyl)- -phenyl]-acetic acid; {4-[(4-Butyl-benzyl)-methanesulfonyl-amino]-butoxy}-acetic acid; Trans-[3-({[3-(3,5-Dichloro-phenyl)-allyl]-methanesulfonyl-amino}-methyl)- -phenoxy]-acetic acid; (4-{[(4-Butyl-benzyl)-methanesulfonyl-amino]-methyl}-phenoxy)-acetic acid; [3-({[3-(3-Chloro-phenyl)-propyl]-methanesulfonyl-amino}-methyl)-ph- enoxy]-acetic acid; [3-({[2-(3,5-Dichloro-phenoxy)-ethyl]-methanesulfonyl-amino}-methyl)-phen- oxy]-acetic acid; (4-{2-[(4-Butyl-benzyl)-methanesulfonyl-amino]-ethyl}-phenyl)-acetic acid; (4-{[2-(3,5-Dichloro-phenoxy)-ethyl]-methanesulfonyl-amino}-butoxy)- -acetic acid; (3-{[(4-Butoxy-benzyl)-methanesulfonyl-amino]-methyl}-phenyl)-acetic acid; {3-[(Benzofuran-2-ylmethyl-methanesulfonyl-amino)-methyl]-phenyl}-a- cetic acid; (3-{[(4-Ethyl-benzyl)-methanesulfonyl-amino]-methyl}-phenyl)-acetic acid; (3-{[Methanesulfonyl-(4-propyl-benzyl)-amino]-methyl}-phenyl)-acetic acid; (3-{[(4-Benzyl-benzyl)-methanesulfonyl-amino]-methyl}-phenyl)-aceti- c acid; (3-{[(4-Butyl-benzyl)-(propane-1-sulfonyl)-amino]-methyl}-phenyl)-- acetic acid; [3-({[4-(1-Hydroxy-hexyl)-benzyl]-methanesulfonyl-amino}-methyl)-phenyl]-- acetic acid; (5-{[(4-Isobutyl-benzyl)-methanesulfonyl-amino]-methyl}-thiophen-2-yl)-ac- etic acid; [5-({[3-Chloro-phenyl)-propyl]-methanesulfonyl-amino}-methyl)-t- hiophen-2-yl]-acetic acid; [5-({[2-(3,5-Dichloro-phenoxy)-ethyl]-methanesulfonyl-amino}-methyl)-thio- phen-2-yl]-acetic acid; (5-{[(4-Butyl-benzyl)-methanesulfonyl-amino]-methyl}-thiophen-2-yl)-aceti- c acid; [3-(3-{[3-(3-Chloro-phenyl)-propyl]-methanesulfonyl-amino}-propyl)- -phenyl]-acetic acid; (3-{[(4-Isobutyl-benzyl)-methanesulfonyl-amino]-methyl}-phenyl)-acetic acid; (2-{3-[(4-Butyl-benzyl)-methanesulfonyl-amino]-propyl}-phenyl)-acet- ic acid; [3-({[2-(3-Chloro-phenoxy)-ethyl]-methanesulfonyl-amino}-methyl)-- phenyl]-acetic acid; [3-(2-{[3-(3-Chloro-phenyl)-propyl]-methanesulfonyl-amino}-ethyl)-phenyl]- -acetic acid; [3-(2-{[2-(3,5-Dichloro-phenoxy)-ethyl]-methanesulfonyl-amino}-ethyl)-phe- nyl)]-acetic acid; (3-{[(2,3-Dihydro-benzo[1,4]dioxin-5-ylmethyl)-methanesulfonyl-amino]-met- hyl}-phenyl-acetic acid; (3-{[(5-Ethyl-thiophen-2-ylmethyl)-methanesulfonyl-amino]-methyl}-phenyl)- -acetic acid; (3-{[Methanesulfonyl-(5-phenyl-furan-2-ylmethyl)-amino]-methyl}-phenyl)-a- cetic acid; (3-{[(3-Hydroxy-4-propoxy-benzyl)-methanesulfonyl-amino]-methyl}-phenyl)-- acetic acid; [3-({[2-(4-Chloro-phenylsulfanyl)-ethyl]-methanesulfonyl-amino}-methyl)-p- henyl]-acetic acid; (3-{[Methanesulfonyl-(4-phenethylsulfanyl-benzyl)-amino]-methyl}phenyl)-a- cetic acid; [3-({[3-(3,5-Dichloro-phenoxy)-benzyl]-methanesulfonyl-amino}-methyl)-phe- nyl]-acetic acid; (3-{[Methanesulfonyl-(4-pyrimidin-2-yl-benzyl)-amino]-methyl}-phenyl)-ace- tic acid; (3-{[Methanesulfonyl-(4-thiazol-2-yl-benzyl)-amino]-methyl}-phen- yl)-acetic acid; (3-{[(4-Benzyl-3-hydroxy-benzyl)-methanesulfonyl-amino]-methyl}-phenyl)-a- cetic acid; (3-{[Methanesulfonyl-(4-pyrazin-2-yl-benzyl)-amino]-methyl}-phenyl)-aceti- c acid; (3-{[Methanesulfonyl-(4-phenoxy-benzyl)-amino]-methyl}-phenyl)-ace- tic acid; [3-({Methanesulfonyl-[4-(4-methyl-[1,2,3]triazol-1-yl)-benzyl]-a- mino}-methyl)-phenyl]-acetic acid; [3-({Methanesulfonyl-[4-(2-oxo-pyrrolidin-1-yl)-benzyl]-amino}-methyl)-ph- enyl]-acetic acid; (3-{[(4-Ethoxy-benzyl)-methanesulfonyl-amino]-methyl}-phenyl)-acetic acid; (3-{[(4-Dimethylamino-benzyl)-methanesulfonyl-amino]-methyl}-phenyl- )-acetic acid; (3-{[(4-Cyclohexyl-benzyl)-methanesulfonyl-amino]-methyl}-phenyl)-acetic acid; (3-{[Methanesulfonyl-(4-pentyl-benzyl)-amino]-methyl}-phenyl)-aceti- c acid; (3-{[(4-Isopropoxy-benzyl)-methanesulfonyl-amino]-methyl}-phenyl)-- acetic acid; (3-{[(Methanesulfonyl-(4-pyrimidin-5-yl-benzyl)-amino]-methyl}-phenyl)-ac- etic acid; (3-{[Methanesulfonyl-(4-methyl-benzyl)-amino]-methyl}-phenyl)-a- cetic acid; (3-{[(4-tert-Butyl-benzyl)-methanesulfonyl-amino]-methyl}-phenyl)-acetic acid; (3-{[(4-tert-Butyl-benzyl)-methanesulfonyl-amino]-methyl}-phenoxy)-- acetic acid; (3-{[Methanesulfonyl-(4-trifluoromethoxy-benzyl)-amino]-methyl}-phenyl)-a- cetic acid; [3-({[3-(4-Chloro-phenyl)-propyl]methanesulfonyl-amino}-methyl)-phenyl]-a- cetic acid; (3-{[Methanesulfonyl-(3-trifluoromethoxy-benzyl)-amino]-methyl}-phenyl)-a- cetic acid; [3-({[2-(3-Chloro-phenylsulfanyl)-ethyl]-methanesulfonyl-amino}-methyl)-p- henyl]-acetic acid; [3-({[4-(2-Benzo[1,3]dioxol-5-yl-vinyl)-benzyl]-methanesulfonyl-amino}-me- thyl)-phenyl]-acetic acid; (3-{[Methanesulfonyl-(4-thiazol-2-yl-benzyl)-amino]-methyl}-phenoxy)-acet- ic acid; (3-{[Methanesulfonyl-(4-pyridin-2-yl-benzyl)-amino]-methyl}-pheno- xy)-acetic acid; (3-{[Methanesulfonyl-(4-pyridin-3-yl-benzyl)-amino]-methyl}-phenoxy)-acet- ic acid; (3-{[(Benzo[1,2,5]oxadiazole-4-sulfonyl)-(4-butyl-benzyl)-amino]-- methyl}-phenyl)-acetic acid; (3-{[(4-Butyl-benzyl)-(propane-1-sulfonyl)-amino]-methyl}-phenyl)-acetic acid; (3-{[(4-Butyl-benzyl)-(thiophene-2-sulfonyl)-amino]-methyl}-phenyl)- -acetic acid; (3-{[(4-Butyl-benzyl)-methanesulfonyl-amino]-methyl}-phenyl)-acetic acid; [3-({[3-(3,5-Dichloro-phenyl)-allyl]-methanesulfonyl-amino}-methyl)-pheno- xy]-acetic acid; [3-({[2-(3,5-Dichloro-phenoxy)-ethyl]-methanesulfonyl-amino}-methyl)-phen- oxy]-acetic acid; (3-{[(4-Cyclohexyl-benzyl)-methanesulfonyl-amino]-methyl}-phenyl)-acetic acid; and (3-{[(4-tert-Butyl-benzyl)-methanesulfonyl-amino]-methyl}-pheno- xy)-acetic acid, or a pharmaceutically acceptable salt thereof.

5. A compound as recited in claim 2 selected from the group consisting of: 4-(2-{[3-(3,5-Dichloro-phenyl)-allyl]-methanesulfonyl-amino}-ethyl)-b- enzoic acid; 3-(2-{[2-(3,5-Dichloro-phenoxy)-ethyl]-methanesulfonyl-amino}-ethoxy)-ben- zoic acid; Trans-4-{2-[Methanesulfonyl-(3-phenyl-allyl)-amino]-ethoxy}-ben- zoic acid; 3-(2-{[2-(3,5-Dichloro-phenoxy)-ethyl]-methanesulfonyl-amino}-e- thyl)-benzoic acid; 3-(3-{[3-(3-Chloro-phenyl)-propyl]-methanesulfonyl-amino}-propyl)-benzoic acid; and 3-(3-{[3-(3-Chloro-phenyl)-propyl]-ethanesulfonyl-amino}-propyl- )-benzoic acid, or a pharmaceutically acceptable salt thereof.

6. A compound as recited in claim 2 selected from the group consisting of: 5-(3-{[3-(3-Chloro-phenyl)-propyl]methanesulfonyl-amino}-propyl)-thio- phene-2-carboxylic acid; 5-{3-[(4-Butyl-benzyl)-methanesulfonyl-amino]-propyl}-thiophene-2-carboxy- lic acid; Trans-5-(3-{[3-(3,5-Dichloro-phenyl)-allyl]-methanesulfonyl-amin- o}-propyl)-thiophene-2-carboxylic acid; 5-(3-{[2-(3,5-Dimethyl-phenoxy)-ethyl]-methanesulfonyl-amino}-propyl)-thi- ophene-2-carboxylic acid; 5-(3-{[2-(3,5-Dimethoxy-phenoxy)-ethyl]-methanesulfonyl-amino}-propyl)-th- iophene-2-carboxylic acid; 5-(3-{[2-(3,5-Dichloro-phenoxy)-ethyl]-methanesulfonyl-amino}-propyl)-thi- ophene-2-carboxylic acid; 5-{3-[(6-Chloro-quinolin-2-ylmethyl)-methanesulfonyl-amino]-propyl}-thiop- hene-2-carboxylic acid; 5-(3-{[2-(3,5-Bis-trifluoromethyl-phenoxy)-ethyl]-methanesulfonyl-amino}-- propyl)-thiophene-2-carboxylic acid; 5-(3-{Methanesulfonyl-[2-(3-methoxy-phenoxy)-ethyl]-amino}-propyl)-thioph- ene-2-carboxylic acid; 5-(3-{[3-(3-Chloro-5-methoxy-phenoxy)-propyl]-methanesulfonyl-amino}-prop- yl)-thiophene-2-carboxylic acid; 5-(3-{[3-(3,5-Dichloro-phenoxy)-propyl]-methanesulfonyl-amino}-propyl)-th- iophene-2-carboxylic acid; 5-(3-{[2-(3-Ethyl-phenoxy)-ethyl]-methanesulfonyl-amino}-propyl)-thiophen- e-2-carboxylic acid; 5-(3-{[2-(3-Isopropyl-phenoxy)-ethyl]-methanesulfonyl-amino}-propyl)-thio- phene-2-carboxylic acid; 5-(3-{Methanesulfonyl-[2-(3-trifluoromethyl-phenoxy)-ethyl]-amino}-propyl- )-thiophene-2-carboxylic acid; 5-{3-[Methanesulfonyl-(3-phenyl-propyl)-amino]-propyl}-thiophene-2-carbox- ylic acid; 5-(3-{Methanesulfonyl-[2-(3-fluoro-phenoxy)-ethyl]-amino}-propy- l)-thiophene-2-carboxylic acid; 5-(3-{Methanesulfonyl-[3-(3-methoxy-phenyl)-propyl]-amino}-propyl-thiophe- ne-2-carboxylic acid; 5-[3-(Benzofuran-2-ylmethyl-methanesulfonyl-amino)-propyl]-thiophene-2-ca- rboxylic acid; 5-(3-{[2-(3-Chloro-5-methoxy-phenoxy)-ethyl]-methanesulfonyl-amino}-propy- l)-thiophene-2-carboxylic acid; 5-(3-{[2-(3-Ethoxy-phenoxy)-ethyl]-methanesulfonyl-amino}-propyl)-thiophe- ne-2-carboxylic acid; 5-{3-[(3-Furan-2-yl-propyl)-methanesulfonyl-amino]-propyl}-thiophene-2-ca- rboxylic acid; 5-(3-{[2-(3-Chloro-phenoxy)-ethyl]-methanesulfonyl-amino}-propyl)-thiophe- ne-2-carboxylic acid; 5-{3-[(3-Benzo[1,3]dioxol-5-yl-propyl)-methanesulfonyl-amino]-propyl}-thi- ophene-2-carboxylic acid; 5-(3-{[2-(Benzo[1,3]dioxol-5-yloxy)-ethyl]-methanesulfonyl-amino}-propyl)- -thiophene-2-carboxylic acid; 5-(3-{[3-(3-Chloro-phenyl)-propyl]-trifluoroacetyl-amino}-propyl)-thiophe- ne-2-carboxylic acid; 5-{3-[(2,3-Dihydro-benzo[1,4]dioxin-6-ylmethyl)-methanesulfonyl-amino]-pr- opyl}-thiophene-2-carboxylic acid; 5-{3-[(4-Dimethylamino-benzyl)-methanesulfonyl-amino]-propyl}-thiophene-2- -carboxylic acid; 5-{3-[(2-Benzylsulfanyl-ethyl)-methanesulfonyl-amino]-propyl}-thiophene-2- -carboxylic acid; 5-(3-{[2-(Biphenyl-2-yloxy)-ethyl]-methanesulfonyl-amino}-propyl)-thiophe- ne-2-carboxylic acid; 5-(3-{[3-(1H-Indol-3-yl)-propyl]-methanesulfonyl-amino}-propyl)-thiophene- -2-carboxylic acid; 5-{3-[(4-tert-Butyl-benzyl)-methanesulfonyl-amino]-propyl}-thiophene-2-ca- rboxylic acid; 5-(3-{[2-(3-Chloro-phenylsulfanyl)-ethyl]-methanesulfonyl-amino}-propyl)-- thiophene-2-carboxylic acid; 5-(3-{[3-(3-Bromo-phenyl)-propyl]-methanesulfonyl-amino}-propyl)-thiophen- e-2-carboxylic acid; 5-(3-{(Butane-1-sulfonyl)-[3-(3-chloro-phenyl)-propyl]-amino}-propyl)-thi- ophene-2-carboxylic acid; 5-{3-[Cyclopropanecarbonyl-(2,3-dihydro-benzo[1,4]dioxin-6-ylmethyl)-amin- o]-propyl}-thiophene-2-carboxylic acid; 5-[3-(Benzofuran-2-ylmethyl-cyclopropanecarbonyl-amino)-propyl]-thiophene- -2-carboxylic acid; 5-(3-{[3-(3-Chloro-phenyl)-propyl]-propionyl-amino}-propyl)-thiophene-2-c- arboxylic acid; 5-(3-{Acetyl-[3-(3-chloro-phenyl)-propyl]-amino}-propyl)-thiophene-2-carb- oxylic acid; 5-{3-[(4-Butyl-benzyl)-(propane-1-sulfonyl)-amino]-propyl}-thiophene-2-ca- rboxylic acid; 5-{3-[(4-Butyl-benzyl)-ethanesulfonyl-amino]-propyl}-thiophene-2-carboxyl- ic acid; 5-(3-{[3-(3-Chloro-phenyl)-propyl]-ethanesulfonyl-amino}-propyl)-- thiophene-2-carboxylic acid; 5-{3-[[3-(3-Chloro-phenyl)-propyl]-(propane-1-sulfonyl)-amino]-propyl}-th- iophene-2-carboxylic acid; 5-{3-[[3-(3-Chloro-phenyl)-propyl]-(3-chloro-propane-1-sulfonyl)-amino]-p- ropyl}-thiophene-2-carboxylic acid; 5-(3-{[3-(3-Chloro-phenyl)-propyl]-hydroxyacetyl-amino}-propyl)-thiophene- -2-carboxylic acid; 5-(3-{[3-(3-Chloro-phenyl)-propyl]-cyclopropanecarbonyl-amino}-propyl)-th- iophene-2-carboxylic acid; 5-(3-{[3-(3-Chloro-phenyl)-propyl]-cyclobutanecarbonyl-amino}-propyl)-thi- ophene-2-carboxylic acid; 5-(3-{[3-(3-Chloro-phenyl)-propyl]-methoxyacetyl-amino}-propyl)-thiophene- -2-carboxylic acid; 5-(3-{Butyryl-[3-(3-chloro-phenyl)-propyl]-amino}-propyl)-thiophene-2-car- boxylic acid; 5-(3-{[3-(3-Chloro-phenyl)-propyl]-methanesulfonyl-amino}-propyl)-thiophe- ne-2-carboxylic acid; and 5-(3-{[2-(3,5-Dichloro-phenoxy)-ethyl]-methanesulfonyl-amino}-propyl)-thi- ophene-2-carboxylic acid, or a pharmaceutically acceptable salt thereof.

7. A compound as recited in claim 2 selected from the group consisting of: 2-(3-{[2-(3,5-Dichloro-phenoxy)-ethyl]-methanesulfonyl-amino}-propyl)- -thiazole-4-carboxylic acid; 2-{3-[Methanesulfonyl-(3-phenyl-propyl)-amino]-propyl}-thiazole-4 carboxylic acid; 2-(3-{[3-(3-Chloro-phenyl)-propyl]-methanesulfonyl-amino}-propyl)-thiazol- e-4-carboxylic acid; 2-{3-[(4-Butyl-benzyl)-methanesulfonyl-amino]-propyl}-thiazole-4-carboxyl- ic acid; 2-{3-[(4-Butyl-benzyl)-methanesulfonyl-amino]-propyl}-thiazole-4-- carboxylic acid; and 2-(3-{[2-(3,5-Dichloro-phenoxy)-ethyl]-methanesulfonyl-amino}-propyl)-thi- azole-4-carboxylic acid, or a pharmaceutically acceptable salt thereof.

8. A compound as recited in claim 2 selected from the group consisting of: 5-(3-{[2-(3,5-Dichloro-phenoxy)-ethyl]-methanesulfonyl-amino}-propyl)- -furan-2-carboxylic acid; Trans-5-(3-{[3-(3,5-Dichloro-phenyl)-allyl]-methanesulfonyl-amino}-propyl- )-furan-2-carboxylic acid; 5-(3-{[3-(3-Chloro-phenyl)-propyl]-methanesulfonyl-amino}-propyl)-furan-2- -carboxylic acid; 5-(3-{[3-(3-Chloro-phenyl)-propyl]-methanesulfonyl-amino}-propyl)-tetrahy- drofuran-2-carboxylic acid; 5-(3-{[3-(3-Chloro-phenyl)-propyl]-ethanesulfonyl-amino}-propyl)-furan-2-- carboxylic acid; 5-(3-{[3-(3-Chloro-phenyl)-propyl]-propionyl-amino}-propyl)-furan-2-carbo- xylic acid; 5-(3-{[3-(3-Chloro-phenyl)-propyl]-cyclopropanecarbonyl-amino}-propyl)-fu- ran-2-carboxylic acid; and 5-(3-{Acetyl-[3-(3-chloro-phenyl)-propyl]-amino}-propyl)-furan-2-carboxyl- ic acid, or a pharmaceutically acceptable salt thereof.

9. A compound as recited in claim 2 selected from the group consisting of: Trans-N-[3-(3,5-Dichloro-phenyl)-allyl]-N-6-(1H-tetrazol-5-yl)-hexyl]- -methanesulfonamide; N-(4-Butyl-benzyl)-N-[6-(2H-tetrazol-5-yl)-hexyl]-methanesulfonamide; N-[2-(3,5-Dichloro-phenoxy)-ethyl]-N-[6-(1H-tetrazol-5-yl)-hexyl]-methane- sulfonamide; and N-[2-(3,5-Dichloro-phenoxy)-ethyl]-N-[6-(1H-tetrazol-5-yl)-hexyl]-methane- sulfonamide, or a pharmaceutically acceptable salt thereof.

10. A method for treating a mammal having a condition which presents with low bone mass comprising administering to said mammal a therapeutically effective amount of a compound of claim 2 or a pharmaceutically acceptable salt or prodrug thereof.

11. The method as recited in claim 10 wherein osteoporosis, osteotomy, childhood idiopathic bone loss or bone loss associated with periodontitis is treated.

12. The method as recited in claim 11 wherein osteoporosis is treated in a human.

13. The method as recited in claim 10 wherein glucocorticoid-induced osteoporosis, hyperthyroidism-induced osteoporosis, immobilization-induced osteoporosis, heparin-induced osteoporosis or immunosuppressive-induced osteoporosis is treated.

14. A method for augmenting and maintaining bone mass in a mammal comprising administering to a mammal a therapeutically effective amount of a compound of claim 2 or a pharmaceutically acceptable salt or prodrug thereof.

15. The method as recited in claim 14 wherein bone healing following facial reconstruction, maxillary reconstruction or mandibular reconstruction is treated, vertebral synostosis is induced or long bone extension is enhanced, the healing rate of a bone graft is enhanced or prosthetic ingrowth is enhanced.

16. The method as recited in claim 14 wherein a bone fracture is treated in a human.

17. A pharmaceutical composition which comprises a therapeutically effective amount of a compound of claim 2 or a pharmaceutically acceptable salt or prodrug thereof and a pharmaceutically acceptable carrier.

18. The pharmaceutical composition as recited in claim 17 for the treatment of osteoporosis wherein the therapeutically effective amount is an osteoporosis treating amount.

19. A pharmaceutical composition for the augmentation of bone mass which comprises a bone mass augmenting amount of a compound of claim 2 or a pharmaceutically acceptable salt or prodrug thereof and a pharmaceutically acceptable carrier.

20. The pharmaceutical composition as recited in claim 19 for the treatment of a bone fracture or a pharmaceutically acceptable salt or prodrug thereof is used.

21. A pharmaceutical composition for the treatment of a condition which presents with low bone mass in a mammal which comprises a low bone mass condition treating amount of a compound of claim 2 or a pharmaceutically acceptable salt or prodrug thereof and a pharmaceutically acceptable carrier.

22. A pharmaceutical composition comprising: a. a therapeutically effective amount of a compound of claim 2 or a pharmaceutically acceptable salt or prodrug thereof; b. a therapeutically effective amount of an anti-resorptive agent; and c. a pharmaceutical carrier.

23. A pharmaceutical composition as recited in claim 22 wherein the anti-resorptive agent is droloxifene, raloxifene, tamoxifen, 4-hydroxy-tamoxifen, toremifene, centchroman, levormeloxifene, idoxifene, 6-(4-hydroxy-phenyl)-5-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-naphthalene-2- -ol, {4-[2-(2-Aza-bicyclo[2.2.1]hept-2-yl)-ethoxy]-phenyl}-[6-hydroxy-2-(4- -hydroxy-phenyl)-benzo[b]thiophen-3-yl]-methanone, Cis-6-(4-fluoro-phenyl)-5-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-5,6,7,8-te- trahydro-naphthalene-2-ol; (-)-Cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahyd- ro-naphthalene-2-ol; Cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-n- aphthalene-2-ol; Cis-1-[6'-pyrrolodinoethoxy-3'-pyridyl]-2-phenyl-6-hydroxy-1,2,3,4-tetrah- ydrohaphthalene; 1-(4'-Pyrrolidinoethoxyphenyl)-2-(4''-fluorophenyl)-6-hydroxy-1,2,3,4-tet- rahydroisoquinoline; Cis-6-(4-hydroxyphenyl)-5-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-5,6,7,8-te- trahydro-naphthalene-2-ol; or 1-(4'-Pyrrolidinolethoxyphenyl)-2-phenyl-6-hydroxy-1,2,3,4-tetrahydroisoq- uinoline or a pharmaceutically acceptable salt thereof.

24. A pharmaceutical composition as recited in claim 22 wherein the anti-resorptive agent is tiludronic acid, alendronic acid, ibandronic acid, risedronic acid, etidronic acid, clodronic acid, and pamidronic acid or a pharmaceutically acceptable salt thereof.

25. A method for treating a mammal having a condition which presents with low bone mass comprising administering to said mammal a. a therapeutically effective amount of a compound of claim 2 or a pharmaceutically acceptable salt or prodrug thereof; and b. a therapeutically effective amount of an anti-resorptive agent.

26. The method as recited in claim 25 wherein the anti-resorptive agent is droloxifene, raloxifene, tamoxifen, 4-hydroxy-tamoxifen, toremifene, centchroman, levormeloxifene, idoxifene, 6-(4-hydroxy-phenyl)-5-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-naphthalen-2-- ol, {4-[2-(2-Aza-bicyclo[2.2.1]hept-2-yl)-ethoxy]-phenyl}-[6-hydroxy-2-(4-- hydroxy-phenyl)-benzo[b]thiophen-3-yl]-methanone, Cis-6-(4-fluoro-phenyl)-5-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-5,6,7,8-te- trahydro-naphthalene-2-ol; (-)-Cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahyd- ro-naphthalene-2-ol; Cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-n- aphthalene-2-ol; Cis-1-[6'-pyrrolodinoethoxy-3'-pyridyl]-2-phenyl-6-hydroxy-1,2,3,4-tetrah- ydrohaphthalene; 1-(4'-Pyrrolidinoethoxyphenyl)-2-(4''-fluorophenyl)-6-hydroxy-1,2,3,4-tet- rahydroisoquinoline; Cis-6-(4-hydroxyphenyl)-5-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-5,6,7,8-te- trahydro-naphthalene-2-ol; or 1-(4'-Pyrrolidinolethoxyphenyl)-2-phenyl-6-hydroxy-1,2,3,4-tetrahydroisoq- uinoline or a pharmaceutically acceptable salt thereof.

27. The method as recited in claim 25 wherein the anti-resorptive agent is, tiludronic acid, alendronic acid, ibandronic acid, risedronic acid, etidronic acid, clodronic acid, and pamidronic acid or a pharmaceutically acceptable salt.

28. A kit comprising: a. a therapeutically effective amount of a compound of claim a 2 or a pharmaceutically acceptable salt or prodrug thereof and a pharmaceutically acceptable carrier in a first unit dosage form; b. a therapeutically effective amount of an anti-resorptive agent and a pharmaceutically acceptable carrier in a second unit dosage form; and c. container means for containing said first and second dosage forms.

29. The kit as recited in claim 28 wherein the anti-resorptive agent is droloxifene, raloxifene, tamoxifen, 4-hydroxy-tamoxifen, toremifene, centchroman, levormeloxifene, idoxifene, 6-(4-hydroxy-phenyl)-5-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-naphthalen-2-- ol, {4-[2-(2-Aza-bicyclo[2.2.1]hept-2-yl)-ethoxy]-phenyl}-[6-hydroxy-2-(4-- hydroxy-phenyl)-benzo[b]thiophen-3-yl]-methanone, Cis-6-(4-fluoro-phenyl)-5-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-5,6,7,8-te- trahydro-naphthalene-2-ol; (-)-Cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahyd- ro-naphthalene-2-ol; Cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-n- aphthalene-2-ol; Cis-1-[6'-pyrrolodinoethoxy-3'-pyridyl]-2-phenyl-6-hydroxy-1,2,3,4-tetrah- ydrohaphthalene; 1-(4'-Pyrrolidinoethoxyphenyl)-2-(4''-fluorophenyl)-6-hydroxy-1,2,3,4-tet- rahydroisoquinoline; Cis-6-(4-hydroxyphenyl)-5-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-5,6,7,8-te- trahydro-naphthalene-2-ol; or 1-(4'-Pyrrolidinolethoxyphenyl)-2-phenyl-6-hydroxy-1,2,3,4-tetrahydroisoq- uinoline or a pharmaceutically acceptable salt thereof.

30. The kit as recited in 28 wherein the anti-resorptive agent is tiludronic acid, alendronic acid, ibandronic acid, risedronic acid, etidronic acid, clodronic acid, and pamidronic acid or a pharmaceutically acceptable salt thereof.

31. A pharmaceutical composition comprising: a. a therapeutically effective amount of a compound of claim 2 or a pharmaceutically acceptable salt or prodrug thereof; b. a therapeutically effective amount of an anabolic agent other than a compound of claim 2 or a pharmaceutically acceptable salt or prodrug thereof; and c. a pharmaceutical carrier.

32. The pharmaceutical composition as recited in claim 31 wherein the anabolic agent is IGF-1 optionally with IGF-1 binding protein 3 prostaglandin, prostaglandin agonist/antagonist, sodium fluoride, parathyroid hormone (PTH), active fragments of parathyroid hormone, growth hormone or growth hormone secretagogues or a pharmaceutically acceptable salt thereof.

33. A method for treating a mammal which presents with low bone mass comprising administering to said a. a therapeutically effective amount of a compound of claim 2 or a pharmaceutically acceptable salt or prodrug thereof; and b. a therapeutically effective amount of a bone anabolic agent other than a compound of claim 2 or a pharmaceutically acceptable salt or prodrug thereof.

34. The method as recited in claim 33 wherein the anabolic agent is IGF-1, prostaglandin, prostaglandin agonist/antagonist, sodium fluoride, parathyroid hormone (PTH), active fragments of parathyroid hormone, growth hormone or growth hormone secretagogues or a pharmaceutically acceptable salt thereof.

35. A kit comprising: a. a therapeutically effective amount of a compound of claim 2 or a pharmaceutically acceptable salt or prodrug thereof and a pharmaceutically acceptable carrier in a first unit dosage form; b. a therapeutically effective amount of an anabolic agent other than a compound of claim 2 or a pharmaceutically acceptable salt or prodrug thereof and a pharmaceutically acceptable carrier in a second unit dosage form; and container means for containing said first and second dosage forms.

36. The kit as recited in claim 35 wherein the anabolic agent is IGF-1, prostaglandin, prostaglandin agonist/antagonist, sodium fluoride, parathyroid hormone (PTH), active fragments of parathyroid hormone, growth hormone or growth hormone secretagogues or a pharmaceutically acceptable salt thereof.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.